Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kymera Therapeutics Inc (NQ: KYMR ) 42.47 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 42.47 Bid (Size) 40.00 (1) Ask (Size) 52.00 (1) Prev. Close 42.47 Today's Range 42.47 - 42.47 52wk Range 9.600 - 48.70 Shares Outstanding 55,307,775 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details July 14, 2024 10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... Via Benzinga Why Kymera Therapeutics Stock Is Soaring Today July 09, 2024 Kymera's lead pipeline candidate received some good news. Via The Motley Fool Performance YTD +67.53% +67.53% 1 Month +35.04% +35.04% 3 Month +23.64% +23.64% 6 Month +45.00% +45.00% 1 Year +93.93% +93.93% More News Read More Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 09, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics June 17, 2024 Via Benzinga Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews May 24, 2024 Via Benzinga Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) April 22, 2024 Via Benzinga Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday July 09, 2024 Via Benzinga Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day July 09, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy July 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 Via FinancialNewsMedia Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting June 14, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 From FN Media Group LLC Via GlobeNewswire Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting June 01, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming June Investor Conferences May 29, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting May 23, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting May 22, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting May 14, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming May Investor Conferences May 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 02, 2024 Via InvestorPlace Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update May 02, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 April 25, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting April 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting March 08, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Kymera Therapeutics to Participate in Upcoming March Investor Conferences February 28, 2024 From Kymera Therapeutics, Inc. Via GlobeNewswire Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know February 27, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
